A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak jajnika oporny na chemioterapię lub powracający po chemioterapii
- •Zaawansowany rak jądra lub zaawansowany rak trzonu macicy
- •Nowotwór musi być widoczny w badaniach obrazowych
- •Pacjent w dobrym stanie ogólnym, mogący funkcjonować w życiu codziennym
- •Przewidywana długość życia co najmniej 12 tygodni
- •Prawidłowe działanie narządów (wątroba, nerki, serce)
✗ Disqualifies
- •Przerzuty nowotworowe do mózgu lub rdzenia kręgowego
- •Nieskontrolowana poważna infekcja
- •Udział w innym badaniu klinicznym w tym samym czasie
- •Schorzenia lub warunki, które mogłyby uniemożliwić bezpieczny udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (15)
University of Arkansas Winthrop P. Rockefeller Cancer Institute
Little Rock, United States
Precision NextGen Oncology & Research Center
Beverly Hills, United States
SCRI at Denver Health
Denver, United States
Dana-Farber Cancer Institute
Boston, United States
University of Nebraska Medical
Omaha, United States
John Theurer Cancer Center
Hackensack, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Duke Cancer Institute
Durham, United States
Gabrail Cancer Center
Canton, United States
Providence Cancer Institute of Oregon
Portland, United States
Fox Chase Cancer Center
Philadelphia, United States
Women & Infants Hospital of Rhode Island
Providence, United States
Vanderbilt-Ingram Cancer Center
Nashville, United States
SCRI at Mary Crowley
Dallas, United States
University College London Hospital
London, United Kingdom
Trial contact
Context Clinical Development
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.